Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Press

Showing results (191-200 of 197) with videos related to

Pageof 20
Sort By:
You have reached the last page of results.This site can display upto 197 results.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 2, 2021
Contributions of Social Factors to Disparities in Prostate Cancer Risk Profiles among Black Men and Non-Hispanic White Men with Prostate Cancer in CaliforniaDavid J Press, Salma Shariff-Marco, Daphne Y Lichtensztajn, et al.
American Journal of Epidemiology|November 27, 2010
Breast cancer risk and ovariectomy, hysterectomy, and tubal sterilization in the women's contraceptive and reproductive experiences studyDavid J Press, Jane Sullivan-Halley, Giske Ursin, et al.
Bioorganic & Medicinal Chemistry Letters|May 7, 2005
A new orally bioavailable dual adenosine A2B/A3 receptor antagonist with therapeutic potentialNeil J Press, Roger J Taylor, Joseph D Fullerton, et al.
Journal of Medicinal Chemistry|August 20, 2015
Discovery and Optimization of 4-(8-(3-Fluorophenyl)-1,7-naphthyridin-6-yl)transcyclohexanecarboxylic Acid, an Improved PDE4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)Neil J Press, Roger J Taylor, Joseph D Fullerton, et al.
American Heart Journal|September 28, 2024
Design and rationale of penn medicine healthy heart, a randomized trial of effectiveness of a centrally organized approach to blood pressure and cholesterol improvement among patients at elevated risk of atherosclerotic cardiovascular diseaseK G Volpp, K Mahraj, L A Norton, et al.
Journal of Medicinal Chemistry|August 15, 2012
Solubility-driven optimization of phosphodiesterase-4 inhibitors leading to a clinical candidateNeil J Press, Roger J Taylor, Joseph D Fullerton, et al.
The New England Journal of Medicine|February 21, 2014
Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathyPaulina Navon Elkan, Sarah B Pierce, Reeval Segel, et al.
Pageof 20

Showing results (191-200 of 197) with videos related to

Sort By:
Pageof 20
You have reached the last page of results.This site can display upto 197 results.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 2, 2021
Contributions of Social Factors to Disparities in Prostate Cancer Risk Profiles among Black Men and Non-Hispanic White Men with Prostate Cancer in CaliforniaDavid J Press, Salma Shariff-Marco, Daphne Y Lichtensztajn, et al.
American Journal of Epidemiology|November 27, 2010
Breast cancer risk and ovariectomy, hysterectomy, and tubal sterilization in the women's contraceptive and reproductive experiences studyDavid J Press, Jane Sullivan-Halley, Giske Ursin, et al.
Bioorganic & Medicinal Chemistry Letters|May 7, 2005
A new orally bioavailable dual adenosine A2B/A3 receptor antagonist with therapeutic potentialNeil J Press, Roger J Taylor, Joseph D Fullerton, et al.
Journal of Medicinal Chemistry|August 20, 2015
Discovery and Optimization of 4-(8-(3-Fluorophenyl)-1,7-naphthyridin-6-yl)transcyclohexanecarboxylic Acid, an Improved PDE4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)Neil J Press, Roger J Taylor, Joseph D Fullerton, et al.
American Heart Journal|September 28, 2024
Design and rationale of penn medicine healthy heart, a randomized trial of effectiveness of a centrally organized approach to blood pressure and cholesterol improvement among patients at elevated risk of atherosclerotic cardiovascular diseaseK G Volpp, K Mahraj, L A Norton, et al.
Journal of Medicinal Chemistry|August 15, 2012
Solubility-driven optimization of phosphodiesterase-4 inhibitors leading to a clinical candidateNeil J Press, Roger J Taylor, Joseph D Fullerton, et al.
The New England Journal of Medicine|February 21, 2014
Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathyPaulina Navon Elkan, Sarah B Pierce, Reeval Segel, et al.
Pageof 20